Detalles de la búsqueda
1.
Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor.
Blood
; 142(1): 62-72, 2023 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36796019
2.
Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
J Biol Chem
; 287(33): 28087-98, 2012 Aug 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-22730329
3.
Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1.
Cell Rep Med
; 4(11): 101282, 2023 11 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37992688
4.
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells.
Oncotarget
; 11(17): 1478-1492, 2020 Apr 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-32391118
5.
A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib.
Oncotarget
; 11(3): 216-236, 2020 Jan 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-32076484
6.
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Cancer Discov
; 10(8): 1174-1193, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32404308
7.
Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.
Mol Cancer Ther
; 18(12): 2207-2219, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31530649
8.
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene.
Cancer Discov
; 9(2): 248-263, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30373917
9.
Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling.
Clin Cancer Res
; 24(23): 6028-6039, 2018 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30131386
10.
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.
Cell Rep
; 22(11): 2978-2994, 2018 03 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-29539425
11.
Preclinical characterization of abemaciclib in hormone receptor positive breast cancer.
Oncotarget
; 8(41): 69493-69507, 2017 Sep 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-29050219
12.
Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration.
Mol Cancer Ther
; 16(12): 2677-2688, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29054982
13.
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.
Cancer Cell
; 32(6): 761-776.e6, 2017 Dec 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29232554
14.
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
Cancer Cell
; 28(3): 384-98, 2015 Sep 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-26343583
15.
Identification of druggable cancer driver genes amplified across TCGA datasets.
PLoS One
; 9(5): e98293, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24874471
Resultados
1 -
15
de 15
1
Próxima >
>>